RepliCel Life Sciences Inc. announced the formation of a clinical advisory board (CAB) to support the clinical development of its RCT-01 autologous cell therapy for the treatment of a variety of chronic tendon injuries including Achilles, patellar and elbow tendinosis. The board, chaired by Ross G. Davidson, MBChB, will provide its expertise and guidance on all aspects of the clinical trial program. Additional members include David A. Connell, MBBS, and Dr. Jack E. Taunton, M.D. Dr. Davidson has facilitated the recovery of numerous high profile professional athletes during his 30 year career in sports medicine.

He is currently a member of the New Zealand Orthopaedic Association and the Canadian Orthopaedic Association. He is the past president of the National Hockey League Physicians Society, past head physician and orthopaedic consultant for the Vancouver Canucks Hockey Club (NHL), past orthopaedic consultant to the Vancouver Grizzlies Basketball Team (NBA), and past orthopaedic consultant to the Canadian Football League Players Association. He is also the Director of the Post-Graduate Programme in Sports Medicine at the University of Auckland.

Dr. Jack Taunton serves as Professor in the Faculty of Medicine, Division of Sports Medicine at the University of British Columbia and has a clinical practice in sports medicine at the Allan McGavin Sports Medicine Centre where he was the director for over 25 years after co-founding the centre in 1979. He served as the Chief Medical Officer (CMO) for the Vancouver 2010 Olympic and Paralympic Winter Games and CMO for Canada at the Sydney Olympics, two Pan American and two World Student Games. Dr. Connell is a recognized international authority on muscle and tendon injuries.

His private practice is dedicated to musculoskeletal radiology and he serves as an associate professor in the Faculty of Medicine at Monash University. In 2010, he established a diagnostic and treatment facility for elite athletes in AAMI stadium, Olympic Park in Melbourne.